Balancing the Risks of Recurrent Ischaemic and Bleeding Events in a Stable Post ACS Population

Area of Science:

• Cardiology
• Clinical Research
• Thrombosis Management

Background:

• Antithrombotic therapy is crucial after acute coronary syndrome (ACS).
• Balancing recurrent ischemic events and bleeding risk is vital for long-term patient management.
• Individualized risk assessment is needed to guide treatment decisions.

Purpose of the Study:

• To develop a model for guiding antithrombotic treatment decisions in ACS survivors.
• To balance the risks of recurrent ischemic events and bleeding.
• To identify patient subgroups with differential risk profiles.

Main Methods:

• A cohort of 5,905 patients surviving 6 months post-ACS was analyzed from an Australian registry.
• A dual binary outcome modeling strategy was employed to determine independent ischemic and bleeding risks.
• Key variables predicting both outcomes were identified, including modified TIGRIS score, revascularization, heart failure, anemia, multivessel disease, readmission, and age.

Main Results:

• Ischemic events (215) were more frequent than bleeding events (49) overall.
• Predictive models for ischemic and bleeding risk showed good discrimination (C-statistics 0.71 and 0.72).
• In patients post-coronary artery bypass grafting (CABG) with comorbidities, bleeding events exceeded ischemic events.

Conclusions:

• Recurrent ischemic events are more common than bleeding events in most ACS survivors 6-24 months post-discharge.
• Post-CABG patients with comorbidities face a higher bleeding risk, warranting attention to modifiable bleeding factors.
• Dual antiplatelet therapy management requires careful consideration in high-risk bleeding patients.